Angiotensin II Administration in Patients With COVID-19 Shock.
Crit Pathw Cardiol
; 20(2): 100-102, 2021 06 01.
Article
in English
| MEDLINE | ID: covidwho-1234149
ABSTRACT
PURPOSE:
To understand the hemodynamic effect of angiotensin II as a vasopressor in patients with shock secondary to COVID-19 infection.METHODS:
A retrospective analysis was performed on all patients at a single center with COVID-19 infection and shock who were treated with angiotensin II. The hemodynamic response to angiotensin II was estimated by recording the mean arterial pressure, norepinephrine equivalent dose (NED) and urine output.RESULTS:
Ten patients with COVID-19 related shock were treated with angiotensin II. Over the initial 6 hours, the average the NED decreased by 30.4% (from 64.6 to 44 µg/min) without a significant change in the mean arterial pressure (0.7% decrease). Six patients experienced at least a 25% reduction in NED by 6 hours, and 2 experienced at least a 50% reduction.CONCLUSIONS:
On average, the hemodynamic response to angiotensin II in COVID-19 related shock was favorable. Two patients had a marked rapid improvement. Given the relationship of SARS-CoV-2 with the renin-angiotensin-aldosterone system, further evaluation of angiotensin II for the treatment of COVID-19 related shock is warranted.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Shock
/
Vasoconstrictor Agents
/
Angiotensin II
/
COVID-19
Type of study:
Experimental Studies
/
Observational study
Topics:
Long Covid
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Crit Pathw Cardiol
Journal subject:
Cardiology
Year:
2021
Document Type:
Article
Affiliation country:
HPC.0000000000000246
Similar
MEDLINE
...
LILACS
LIS